8-K: Carisma Therapeutics Secures Conditional Nasdaq Listing Extension, Transfers to Capital Market

Carisma Therapeutics Inc. has received a conditional extension from Nasdaq to maintain its listing, transferring to The Nasdaq Capital Market while facing strict compliance deadlines for bid price and market value.

Summary

• Carisma Therapeutics Inc. (CARM) received notice from The Nasdaq Stock Market LLC (Nasdaq) on June 10, 2025, granting its request to continue listing, subject to specified conditions.
• The company's listing is expected to be transferred to The Nasdaq Capital Market, effective as of the open of business on June 12, 2025.
• Carisma previously received notices of non-compliance with Nasdaq Listing Rule 5450(b)(2)(A) (minimum market value of listed securities of $50.0 million, MVLS Rule) on October 10, 2024, and failed to regain compliance by April 8, 2025.
• On April 10, 2025, Nasdaq notified the company of non-compliance with Nasdaq Listing Rule 5450(b)(2)(C) (minimum market value of publicly held shares of $15.0 million, MVPHS Rule).
• On January 6, 2025, Nasdaq notified the company of non-compliance with Nasdaq Listing Rule 5450(a)(1) (minimum bid price of $1.00 per share, Bid Price Rule).
• The extension is subject to the company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions.
• The company must also complete a strategic transaction and otherwise demonstrate compliance with all initial listing requirements for the Nasdaq Capital Market.
• All conditions must be met on or before October 7, 2025, which is also the final deadline for the MVPHS Rule compliance.
• An interim milestone for a strategic transaction is also required.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company avoided immediate delisting, it remains in a precarious position with multiple non-compliance issues and strict conditions to meet by a firm deadline. The transfer to the Nasdaq Capital Market also indicates a lower tier of listing.

Positives

• The Nasdaq Hearings Panel granted Carisma Therapeutics an extension, preventing immediate delisting of its securities.
• The company's listing will be transferred to The Nasdaq Capital Market, allowing it to maintain a presence on Nasdaq, albeit on a different tier.

Negatives

• Carisma Therapeutics is currently non-compliant with multiple Nasdaq listing rules, including minimum market value of listed securities ($50.0 million), minimum market value of publicly held shares ($15.0 million), and minimum bid price ($1.00 per share).
• The company failed to regain compliance with the MVLS Rule by its April 8, 2025 deadline.
• The transfer to The Nasdaq Capital Market may be perceived as a downgrade from The Nasdaq Global Market.
• The extension is subject to strict conditions and a firm deadline of October 7, 2025, with no further discretion for extensions beyond this date.

Risks

• There is no assurance that the Company will be able to satisfy the requirements or conditions for continued listing within the period of time granted by the Panel.
• The Panel has the right to reconsider its determination based on any event, condition or circumstance that would make continued listing inadvisable or unwarranted.
• The Panel does not have discretion to grant continued listing for noncompliance with Nasdaq listing standards beyond October 7, 2025.
• Forward-looking statements are subject to certain risks and uncertainties that may cause the Company's actual results to differ from expectations, including meeting Nasdaq compliance standards.

Future Outlook

Carisma Therapeutics Inc. must achieve a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions, complete a strategic transaction, and otherwise demonstrate compliance with all initial listing requirements for the Nasdaq Capital Market by October 7, 2025. The company also needs to meet an interim milestone for a strategic transaction.

Management Comments

• The Company presented to the Panel its plan to achieve compliance with applicable Nasdaq listing criteria and requested an extension of time to do so.

Industry Context

This announcement reflects a common challenge faced by smaller biotechnology companies, particularly those in clinical development stages, which often experience volatility in share price and market capitalization, making it difficult to maintain Nasdaq's quantitative listing standards. Maintaining a Nasdaq listing is crucial for liquidity and investor confidence in the biotech sector.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's listing status and potential future dilution if the strategic transaction involves equity financing.
• Employees and customers may experience uncertainty regarding the company's long-term stability and operational continuity.
• The transfer to The Nasdaq Capital Market might affect the company's visibility and liquidity for investors.

Next Steps

• Achieve a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions.
• Complete a strategic transaction.
• Demonstrate compliance with all initial listing requirements for The Nasdaq Capital Market.
• Meet an interim milestone for a strategic transaction.
• All conditions must be met on or before October 7, 2025.

Key Dates

Recommendation

Keywords

Carisma Therapeutics, Nasdaq, Listing Compliance, 8-K Filing, Market Value, Bid Price, Delisting, Strategic Transaction, Biotechnology, CARM